What does this research mean for the field?

Liquid biopsy techniques, specifically the detection of circulating tumor DNA and circulating tumor cells, offer a minimally invasive method for disease monitoring and treatment decision-making and are increasingly being incorporated into clinical management algorithms across multiple malignancies. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the clinical applications and integration of circulating tumor DNA and circulating tumor cells in precision oncology, spanning diagnosis, screening, response monitoring, and surveillance.

September 2, 2026Indian Journal of Medical and Paediatric OncologyOpen Access

Liquid Biopsy in Precision Oncology: Clinical Applications of Circulating Tumor DNA and Circulating Tumor Cells

View Full Paper

Ask AI

Bookmark

Authors

PGPrabhat GanjuHomi Bhabha National Institute

Discussion

Member takes

Implication

Review demonstrates the clinical utility of circulating tumor biomarkers across multiple malignancies, highlighting a shift toward minimally invasive precision oncology.

Key Points

To review the clinical applications and integration of circulating tumor DNA and circulating tumor cells in precision oncology, spanning diagnosis, screening, response monitoring, and surveillance.
Synthesized current clinical evidence and management algorithms regarding liquid biopsy applications in cancer care.
Evaluated the diagnostic and therapeutic utility of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) across diverse solid malignancies.
Circulating tumor DNA and circulating tumor cells enable minimally invasive detection of actionable molecular abnormalities for real-time therapy selection.
Liquid biopsy platforms effectively track therapeutic response and facilitate longitudinal disease surveillance, supporting their integration into standard clinical management pathways.

Cite This Study

Prabhat Ganju (2026) studied this question.

synapsesocial.com/papers/6a97e249c562ede874ec65c1 https://doi.org/10.1055/s-0046-1825870

View Full Paper

Ask AI

Bookmark

Implication

Review demonstrates the clinical utility of circulating tumor biomarkers across multiple malignancies, highlighting a shift toward minimally invasive precision oncology.

Liquid Biopsy in Precision Oncology: Clinical Applications of Circulating Tumor DNA and Circulating Tumor Cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Liquid Biopsy in Precision Oncology: Clinical Applications of Circulating Tumor DNA and Circulating Tumor Cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider